A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia

A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia

Abstract Background Relapsed/refractory (R/R) multiple myeloma (MM) patients and primary plasma cell leukemia (PCL) have an unfavorable prognosis and no effective treatment. This study was designed to assess the safety and preliminary efficacy of a novel anti‐B‐cell maturation antigen (BCMA) chimeri...

Full description

Bibliographic Details
Main Authors: Chunrui Li, Wenyue Cao, Yimei Que, Qiuxiang Wang, Yi Xiao, Chaojiang Gu, Di Wang, Jue Wang, Lijun Jiang, Hao Xu, Jinhuan Xu, Xiaoxi Zhou, Zhenya Hong, Na Wang, Liang Huang, Shangkun Zhang, Liting Chen, Xia Mao, Min Xiao, Wei Zhang, Li Meng, Yang Cao, Tongcun Zhang, Jian Li, Jianfeng Zhou
Format: Article
Language:English
Published: Wiley 2021-03-01
Series:Clinical and Translational Medicine
Subjects:
anti‐BCMA CAR T cell
multiple myeloma
plasma cell leukemia
relapsed/refractory
Online Access:https://doi.org/10.1002/ctm2.346

Internet

https://doi.org/10.1002/ctm2.346

Similar Items